A study in Health Affairs finds no difference in quality between high and low-priced physicians.
According to research published in Health Affairs use of a tiered network reduced health spending.
Product manufacturers provide a lot of payments and items of value to doctors (all certainly out of the goodness of their hearts) says an analysis in JAMA.
A report from the Blue Cross Blue Shield Association condemns pricing of brand-name drugs as the major driver of drug spending growth.
A report from QuintilesIMS projects “moderate” growth in drug spending through 2021.
A study in the Journal of Health Economics finds that hospitals that merge are able to reduce costs, but payers and consumers don’t see the benefits.
Research carried in JAMA reviews the effect of limiting drug rep interactions with physicians on prescriptions.
A study sponsored by the Health Care Cost Institute and published in Health Affairs looks at variation in prices paid by commercial health plans.
Research carried in JAMA Internal Medicine suggests giving physicians price information doesn’t change what they order.
Another study confirms that the CMS hospital readmission program is poorly designed and isn’t accomplishing squat.